Aktywność biologiczna modyfikowanych nukleozydów. Część 3

Szlenkier, M.

Artykuł - szczegóły

Tytuł artykułu

Aktywność biologiczna modyfikowanych nukleozydów. Część 3

Autorzy

Szlenkier M.

Treść / Zawartość

Pełne teksty:

Pobierz

Identyfikatory

Warianty tytułu

Biological activity of modified nucleosides. Part 3

Języki publikacji

Abstrakty

Part III of the review devoted to biological activities of nucleoside derivatives presents a further description of analogues modified in the sugar residue with particular focus on those with altered configuration in the 2’ or 3’ position, e.g. cytarabine – an old anticancer chemotherapy agent used to treat acute myeloid leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphomas; fludarabine – derivative of vidarabine used as a drug in the treatment of chronic lymphocytic leukemia, and non-Hodgkin lymphomas; clofarabine – approved by the FDA in 2004, a new-generation second-line drug for recurrent acute myeloid leukemia; and fialuridine – examined as a potential therapeutic for the treatment of HBV infection, however, clinical trials ended tragically. In the last section of the review derivatives with other modifications in the sugar moiety are described – carbocyclic and acyclic analogues, l-nucleosides and 5’-modified nucleosides. Among others, very important modified nucleosides are listed e.g. acyclovir, ganciclovir, DHPA, tenofovir, cyclopentenylcytosine, entecavir, carbovir, abacavir, lamivudine, telbivudine and sinefungin VA. All parts together make a possibly complete and concise review, including the latest reports, the most important groups of modified nucleosides, and should be considered as a whole. In the context of the activities description, there are references to the important molecular targets, mechanisms of action, pharmacodynamics, pharmacokinetics, toxicity, resistance, in vitro and in vivo tests or prodrug strategies, which can be a starting point for further study for chemists interested in medicinal chemistry.

Słowa kluczowe

nukleozydy modyfikowane aktywność biologiczna cele molekularne mechanizm działania

modified nucleosides biological activity molecular targets mechanism of action

Wydawca

Polskie Towarzystwo Chemiczne

Czasopismo

Wiadomości Chemiczne

Rocznik

2018

Tom

[Z] 72, 9-10

Strony

767--787

Opis fizyczny

Bibliogr. 77 poz., schem.

Twórcy

autor

Szlenkier M.

mszlenk@ibch.poznan.pl

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk w Poznaniu, ul. Z. Noskowskiego 12/14, 61-704 Poznań

Bibliografia

[1] W.A. Creasy, Handb. Exp. Pharmacol., 1975, 38, 232.
[2] G.A. Gentry, J.F. Aswell, Virology, 1975, 65, 1, 294.
[3] T.W. North, S.S. Cohen, Pharmacol. Ther., 1979, 4, 81.
[4] J.A. Montgomery, K. Hewson, J. Med. Chem., 1969, 12, 498.
[5] L.B. Allen, H.C. Schröder, H.G. Löbering, A. Maidhof, W.E. Müller, Chemotherapy, 1987, 33, 272.
[6] T. Ooka, A. Calender, M. De Turenne, J. Daillie, J. Virol., 1983, 46, 187.
[7] K.F. Soike, G. Baskin, C. Cantrell, P. Gerone, Antiviral Res., 1984, 4, 245.
[8] M. Sarkar, T. Han, V. Damaraju, P. Carpenter, C.E. Cass, R.P. Agarwal, Biochem. Pharmacol., 2005, 70, 426.
[9] W.W. Lee, A. Benitez, L. Goodman, B.R. Baker, J. Am. Chem. Soc., 1960, 82, 2648.
[10] M. Privat de Garilhe, J. de Rudder, C. R. Acad. Sci., 1964, 259, 2725.
[11] W.M. Shannon, L. Westbrook, F.M. Schabel, Proc. Soc. Exp. Biol. Med., 1974, 145, 542.
[12] M. Suzuki, T. Okuda, K. Shiraki, Antiviral Res., 2006, 72, 2, 157.
[13] L. Li, M.J. Keating, W. Plunkett, L.Y. Yang, Mol. Pharmacol., 1997, 52, 798.
[14] D. Wyczechowska, K. Fabianowska-Majewska, Biochem. Pharmacol., 2003, 65, 219.
[15] G.M. Carbone, C.V. Catapano, D.J. Fernandes, Biochem. Pharmacol., 2001, 1, 101.
[16] P. Bojanowski, P.F. Lipiński, P. Czekała, D. Plewczyński, Biul. Wydz. Farm. WUM 2013, 1, 1.
[17] T. Robak, A. Korycka, E. Lech-Maranda, P. Robak, Molecules, 2009, 14, 1183.
[18] L.W. Dow, D.E. Bell, L. Poulakos, A. Fridland, Cancer Res., 1980, 40, 1405.
[19] R.W. Brockman, Y.-C. Cheng, F.M. Schabel, J.A. Montgomery, Cancer Res., 1980, 40, 3610.
[20] M.J. Keating, P. McLaughlin, W. Plunkett, L.E. Robertson, S. O'Brien, Ann. Oncol., 1994, 5, Sup. 2, S79.
[21] P.L. Bonate, L. Arthaud, W.R. Jr Cantrell, K. Stephenson, J.A. 3rd Secrist, S. Weitman, Nat. Rev. Drug Discov., 2006, 5, 855.
[22] W.B. Parker, S.C. Shaddix, C.H. Chang, E.L. White, L.M. Rose, R.W. Brockman, A.T. Shortnacy, J.A. Montgomery, J.A. 3rd Secrist, L.L. Jr. Bennett, Cancer Res., 1991, 51, 2386.
[23] K. Lotfi, E. Månsson, T. Spasokoukotskaja, B. Pettersson, J. Liliemark, Clin. Cancer Res., 1999, 5, 2438.
[24] S. Nagai, K. Takenaka, D. Nachagari, C. Rose, K. Domoney, Cancer Res., 2011, 71, 1781.
[25] N. Shakya, M.C. Srivastav, N. Desroches, B. Agrawal, D.Y. Kunimoto, R. Kumar, J. Med. Chem., 2010, 53, 4130.
[26] I. Fourel, J. Li, O. Hantz, C. Jacquet, J.J. Fox, C. Trépo, J. Med. Virol., 1992, 37, 122.786
[27] R. McKenzie, M.W. Fried, R. Sallie, H. Conjeevaram, A.M. Di Bisceglie, N. Engl. J. Med., 1995, 333, 1099.
[28] W. Lewis, R.R. Meyer, J.F. Simpson, J.M. Colacino, F.W. Perrino, Biochem., 1994, 33, 14620.
[29] Y.C. Cheng, G. Dutschman, J.J. Fox, K.A. Watanabe, H. Machida, Antimicrob. Agents Chemother., 1981, 20, 420.
[30] J.M. Colacino, C. Lopez, Antimicrob. Agents Chemother., 1983, 24, 505.
[31] D.B. Ellis, G.A. LePage, Mol. Pharmacol., 1965, 1, 231.
[32] J. Jansons, Y. Maurinsh, M. Lidaks, Nucleosides Nucleotides, 1995, 14, 1709.
[33] D. Lavanchy, J. Viral. Hepat., 2004, 11, 97.
[34] N.C. Srivastav, N. Shakya, M. Mak, B. Agraval, D.L. Tyrell, R. Kumar, J. Med. Chem., 2010, 53, 7156.
[35] G. Gosselin, M.C. Bergogne, J. De Rudder, E. De Clercq, J.L. Imbach, J. Med. Chem., 1986, 29, 203.
[36] T.R. Webb, H. Mitsuya, S. Broder, J. Med. Chem., 1988, 31, 1475.
[37] N.C. Srivastav, M. Mak, B. Agrawal, D.L.J. Tyrrell, R. Kumar, Bioorg. Med. Chem. Lett., 2010, 20, 6790.
[38] E.S.H. El Ashry, Y. El Kilany, Adv. Heterocycl. Chem., 1997, 69, 129.
[39] J. Boryski, J. Chem. Soc., Perkin Trans 2, 1997, 649.
[40] G.B. Elion, P.A. Furman, J.A. Fyfe, P. de Miranda, L. Beauchamp, H.J. Schaeffer, Proc. Natl. Acad. Sci. USA., 1977, 74, 5716.
[41] E. De Clercq, J. Neyts, Handb. Exp. Pharmacol., 2009, 189, 53.
[42] K.K. Ogilvie, U.O. Cheriyan, B.K. Radatus, K.O. Smith, K.K. Galloway, W.L. Kennell, Can. J. Chem., 1982, 60, 3005.
[43] A.K. Field, M.E. Davies, C. DeWitt, H.C. Perry, R. Liou, J. Germershausen, J.D. Karkas, W.T. Ashton, D.B. Johnston, R.L. Tolman, Proc. Natl. Acad. Sci. USA, 1983, 80, 4139.
[44] D.F. Smee, J.C. Martin, J.P.H. Verheyden, T.R. Matthews, Antimicrob. Agents Chemother., 1983, 23, 676.
[45] V.R. Freitas, D.F. Smee, M. Chernow, R. Boehme, T.R. Matthews, Antimicrob. Agents Chemother., 1985, 28, 240.
[46] T.A. Krenitsky, W.W. Hall, P. De Miranda, Proc. Natl. Acad. Sci. USA, 1984, 81, 3209.
[47] E. De Clercq, J. Descamps, P. De Somer, A. Holý, Science, 1978, 200, 563.
[48] E. De Clecq, Antiviral agents, Elsevier, San Diego, 2013.
[49] L.A. Agrofoglio, S.R. Challand, Acyclic, Carbocyclic and L-nucleosides, Kluwer Academic Publishers, Dordrecht 1998.
[50] R. Borchardt, B. Keller, U. Patel-Thrombe, J. Biol. Chem., 1984, 259, 4353.
[51] E. De Clercq, Antimicrob. Agents. Chemother., 1985, 28, 84.
[52] S. Shuto, T. Obara, Y. Saito, G. Andrei, R. Snoeck, E. De Clercq, A. Matsuda, J. Med. Chem., 1996, 39, 2392.
[53] E. De Clercq, J. Murase, V. Marquez, Biochem. Pharmacol., 1991, 41, 1821.
[54] V.E. Marquez, M.I. Lim, S.P. Treanor, J. Plowman, M.A. Priest, A. Markovac, M.S. Khan, B. Kaskar, J.S. Driscoll, J. Med. Chem., 1988, 31, 1687.
[55] M. Hasobe, H. Liang, D.B. Ault-Riche, D.R. Borcherding, M.S. Wolfe, R.T. Borchardt, Antivir. Chem. Chemother., 1993, 4, 245.
[56] E. De Clercq, Nucleos. Nucleot. Nucl., 2005, 24, 1395.
[57] E.W. Dunham, R. Vince, J. Pharmacol. Exp. Ther., 1986, 238, 954.
[58] Y.F. Shealy, C.A. O'Dell, W.M. Shannon, G.J. Arnett, J. Med. Chem., 1984, 27, 1416.
[59] W.B. Parker, S.C. Shaddix, P.W. Allan, G. Arnett, L.M. Rose, W.M. Shannon, Y.F. Shealy, J.A. Montgomery, J.A. 3rd Secrist, L.L. Jr. Bennett, Mol. Pharmacol., 1992, 41, 245.787
[60] A.D. Borthwick, B.E. Kirk, K. Biggadike, A.M. Exall, S. Butt, S.M. Roberts, D.J. Knight, J.A.V. Coates, D.M. Ryan, J. Med. Chem., 1991, 34, 907.
[61] G.S. Bisacchi, S.T. Chao, C. Bachard, J.P. Daris, S. Innaimo, G.A. Jacobs, O. Kocy, P. Lapointe, A. Martel, Z. Merchant, W.A. Slusarchyk, J.E. Sundeen, M.G. Young, R. Colonno, R. Zahler, Bioorg. Med. Chem. Lett., 1997, 7, 127.
[62] J. Balzarini, E. De Clercq, H. Baumgartner, E. Bodenteich, H. Griengl, Mol. Pharmacol., 1990, 37, 395.
[63] Y. Nishiyama, N. Yamamoto, K. Takahash, N. Shimada, Antimicrob. Agents Chemother., 1988, 32, 1053.
[64] R. Vince, M. Hua, J. Med. Chem., 1990, 33, 17.
[65] S.M. Daluge, S.S. Good, M.B. Faletto, W.H. Miller, M.H. St. Clair, L.R. Boone, M. Tisdale, N.R. Parry, J.E. Reardon, R.E. Dornsife, D.R. Averett, T.A. Krenitsky, Antimicrob. Agents Chemother., 1997, 41, 1082.
[66] J.A.V. Coates, N. Cammack, H.J. Jenkinson, I.M. Mutton, B.A. Pearson, R. Storer, J.M. Cameron, C.R. Penn, Antimicrob. Agents Chemother., 1992, 36, 202.
[67] R.F. Schinazi, A. McMillan, D. Cannon, R. Mathis, R.M. Lloyd, A. Peck, J.P. Sommadossi, M. St Clair, J. Wilson, P.A. Furman, Antimicron. Agents Chemother., 1992, 26, 2423.
[68] C.K. Chu, S. Ahn, H. Kim, J.W. Beach, A.J. Alves, L.S. Jeong, Q. Islam, P. Van Roey, R.F. Schinazi, Tetrahedron Lett., 1991, 32, 3791.
[69] G. Gosselin, R.F. Schinazi, J.P. Sommadossi, C. Mathé, M.C. Bergogne, A.M. Aubertin, A. Kirn, J.L. Imbach, Antimicrob. Agents Chemother., 1994, 38, 1292.
[70] C.K. Chu, T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S.B. Pai, G.Q. Yao, J.P. Sommadossi, Y.C. Cheng, Antimicrob. Agents Chemother., 1995, 39, 979.
[71] W. Lewis, B.J. Day, W.C. Copeland, Nat. Rev. Drug Discov., 2003, 2, 812.
[72] S. Spadari, G. Maga, F. Focher, G. Ciarrocchi, R. Manservigi, F. Arcamone, M. Capobianco, A. Carcuro, F. Colonna, A. Garbesi, J. Med. Chem., 1992, 35, 4214.
[73] M.L. Bryant, E.G. Bridges, L. Placidi, A. Faraj, A.G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J.L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, P. Marion, E. Cretton-Scott, R.F. Schinazi, J.P. Sommadossi, Antimicrob. Agents Chemother., 2001, 45, 229.
[74] D. Gotlieb, P.D. Shaw, Antibiotics I Mechanism of Action, Springer-Verlag, Berlin Heidelberg Gmbh, 1967.
[75] M. Niitsuma, J. Hashida, M. Iwatsuki, M. Mori, A. Ishiyama, M. Namatame, A. Nishihara-Tsukashima, A. Matsumoto, Y. Takahashi, H. Yamada, K. Otoguro, K. Shiomi, S. Omura, J. Antibiot., 2010, 63, 673.
[76] S. Velazquez, A. San-Felix, M.J. Perez-Perez, J. Balzarini, E. De Clercq, M.J. Camarasa, J. Med. Chem., 1993, 36, 3230.
[77] J. Shelton, X. Lu, J.A. Hollenbaugh, J.H. Cho, F. Amblard, R.F. Schinazi, Chem. Rev., 2016, 116, 14379.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-b438718b-bfb9-49a4-9537-c786cd54d25c